ArticleIntensive care medicine2020
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.
Erratum issued 24 registry-linked trialsAbstract readLetter
In one paragraph
Article in Intensive care medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 24 registered trials, which are not on this map. Cited by 2,781 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
2,781citing papers in PubMed, 4 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Anti-inflammatory/Antioxidant Oral Nutrition Supplementation on the Cytokine Storm and Progression of COVID-19: A Randomized Controlled Trial
Efficacy and Safety of Tocilizumab in the Treatment of Patients With Respiratory Distress Syndrome and Cytokine Release Syndrome Secondary to COVID-19: a Proof of Concept Study
CORON-ACT - a Multicenter, Double-blind, Randomized Controlled Phase II Trial on the Efficacy and Safety of Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)
Hemodynamic Characteristics of Patients With SARS-CoV-2: PiCCOVID Study
The Role of Adaptive Immunity in COVID-19 Associated Myocardial Injury
PATCH 2 & 3: (Prevention and Treatment of COVID-19 With Hydroxychloroquine) A Double-blind Placebo Controlled Randomized Trial of Hydroxychloroquine in the Prevention and Treatment of COVID-19
Novel Extracorporeal Treatment to Modulate Hyperinflammation in COVID-19 Patients
Determination of the dose and effectiveness of convalescent plasma in severely and very severely ill patients by covid-19
Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19)
A Prospective, Randomized, Controlled Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms (SAVIOR)
COVID-19 in Hospitalised Patients With Preexisting CArdioVascular Diseases and/or Cardiac Involvement and/or Cardiovascular Risk Factors: the Global PCHF-COVICAV Registry
Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients in Teodoro Maldonado Carbo Specialty's Hospital Infected and Diagnosed by SARS-Cov-2 With COVID-19
Does Therapeutic Plasma Exchange Have A Role in Resistant Cytokine Storm State Of COVID-19 Infection?
Efficacy and Safety of Sirolimus for Treating COVID-19 Infection
Randomized Open Controlled Clinical Trial to Evaluate the Effectiveness of a Eucaloric Ketogenic Nutrition in Comparison With a Standard Nutrition in Covid-19 Disease in Reducing Cytokine Storm Syndrome and ARDS
Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection
Managing Endothelial Dysfunction in COVID-19 : A Randomized Controlled Trial at the Lebanese American University Medical Center- Rizk Hospital
A Phase I-Ib, Double-blinded, Randomized Repeated Dose Single Center, Safety and Immunogenicity Study of Nasal Poly-ICLC (Hiltonol®) in Healthy COVID-19 Vaccinated Adults
NCT04798716 phase1 / phase2unknown statusnot on this mapstarted 2023, after this paper: background citation
Mesenchymal Stem Cell Exosomes for the Treatment of COVID-19 Positive Patients With Acute Respiratory Distress Syndrome and/or Novel Coronavirus Pneumonia
DEXamethasone EARLY Administration in Hospitalized Patients With Covid-19 Pneumonia and High Risk of Developing Acute Respiratory Distress Syndrome
Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients
Longer-term Effects of COVID-19 on Blood Vessels and Blood Pressure (LOCHINVAR) Phenotyping Study
Hemoperfusion With the Efferon CT Extracorporeal Adsorbers Containing Mesoporous Styrene-divinylbenzene Copolymer in Patients With Severe Covid-19
Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation (MANIFEST)
Who cites it
2,781 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Effects of Traditional Chinese Medicine on Restoroing the immune balance of mild-to-moderate Patients with new coronavirus.Indian journal of pharmacology · 2026Pooled it
- Genetic and Epigenetic Determinants of COVID-19 Susceptibility: A Systematic Review.Current medicinal chemistry · 2025Pooled it
- COVID-19 in patients with Down syndrome: A systematic review.Immunity, inflammation and disease · 2024Pooled it
- Serum C-reactive protein greater than 75 mg/dL as an early available laboratory predictor of severe COVID-19: A systematic review.Immunity, inflammation and disease · 2023Pooled it
- Effectiveness and safety of cyclosporine A in moderate to severe COVID-19: a randomized, open-label trial.Scientific reports · 2026Trial
- Trial
- Effect of vitamin D status on a disintegrin-like and metalloprotease with thrombospondin type 1 motif 13 (ADAMTS13) and interleukin 6 in patients with acute myeloid leukaemia.European journal of medical research · 2025Trial
- Use of defibrotide in COVID-19 pneumonia: comparison of a phase II study and a matched real-world cohort control.Haematologica · 2024Trial
- Efficacy and safety of trimodulin in patients with severe COVID-19: results from a randomised, placebo-controlled, double-blind, multicentre, phase II trial (ESsCOVID).European journal of medical research · 2024Trial
- Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial).British journal of cancer · 2024Trial
- Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.Nature communications · 2024Trial
- Development and validation of a prognostic model based on clinical laboratory biomarkers to predict admission to ICU in Omicron variant-infected hospitalized patients complicated with myocardial injury.Frontiers in immunology · 2024Trial
- From discovery through emergency use to the present: Safety evaluation of the COVID-19 mRNA-1273 (Moderna) vaccine.Human vaccines & immunotherapeutics · 2026Review
- Acute and chronic kidney injury following COVID-19 infection and vaccination: a narrative review.European journal of translational myology · 2026Article
- Risk Factors of Secondary Bacterial Infection in Patients Hospitalized with COVID-19.Journal of clinical medicine · 2026Article
- Whole genome sequencing of SARS-CoV-2: evaluating the genetic diversity of variants circulating in Ebonyi State, Southeastern Nigeria.BMC infectious diseases · 2026Article
- Association Between Periodontal Health Status and COVID-19 Severity: A Cross-Sectional Study.Medicina (Kaunas, Lithuania) · 2026Article
- Effects of graphene photothermal adjuvant therapy in patients infected with the Omicron BF.7 variant 2022: a prospective randomized controlled trial.Scientific reports · 2026Article
- New Simplified White Blood Cells Score Improves Mortality Prediction in Severe COVID-19 Patients.Journal of clinical medicine · 2026Article
- Pre-Existing Heart Failure, Biomarker Profiles, and Patients' Vulnerability in Hospitalized COVID-19: A Biomarker-Driven Risk Framework.Journal of clinical medicine · 2026Article
2,721 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
5 authors.
Qiurong RuanInstitute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, Hubei, China.ORCID http://orcid.org/0000-0002-7015-7666
Kun YangDepartment of Dermatology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, Hubei, China.ORCID http://orcid.org/0000-0001-6729-2552
Wenxia WangDepartment of Infectious Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, Hubei, China.ORCID http://orcid.org/0000-0003-4369-6661
Lingyu JiangDepartment of Clinical Immunology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, Hubei, China.ORCID http://orcid.org/0000-0002-2072-0107
Jianxin SongDepartment of Infectious Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, 430030, Hubei, China. songsingsjx@sina.com.ORCID http://orcid.org/0000-0002-4090-6670
Funding
Young Scientists Fund 81602722Young Scientists Fund 81703174
Abstract
PubMed holds no abstract for this paper.
Indexed as
BetacoronavirusRisk AssessmentChinaCoronavirus InfectionsCOVID-19FemaleHumansMalePandemicsPneumonia, ViralRisk FactorsSARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT04323228ClinicalTrials.gov
NCT04332913ClinicalTrials.gov
NCT04335071ClinicalTrials.gov
NCT04337983ClinicalTrials.gov
NCT04340921ClinicalTrials.gov
NCT04353037ClinicalTrials.gov
and 18 more above
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.